IEDPPFNSL is a linear peptidic epitope (epitope ID 25756) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays
The EBV (LMP2) Peptide Pool from peptides&elephants is designed for advanced T cell stimulation and epitope mapping in immunological studies of Epstein-Barr virus (EBV, HHV-4). This peptide pool consists of 122 synthetic 15-mer peptides, overlapping by 11 amino acids, and covers the full sequence of the Latent Membrane Protein 2 (LMP2) (UniProt ID: P13285). LMP2 is a latency-associated antigen commonly expressed in EBV-related malignancies such as nasopharyngeal carcinoma and Hodgkin’s lymphoma. It is a known target of both CD4⁺ and CD8⁺ T cell responses. Each unit of the peptide pool allows for the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is optimized for use in T cell assays, such as ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based functional readouts. Scientific Background LMP2 is one of the most clinically relevant antigens for therapeutic EBV vaccine development, particularly in the context of EBV-associated cancers such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease (PTLD). Therapeutic vaccine candidates using viral vectors encoding LMP2 have successfully induced virus-specific CD8⁺ T cell responses in early-phase clinical trials. Furthermore, adoptive T cell therapies like posoleucel also target LMP2 alongside other latency proteins such as EBNA1, reinforcing its significance as a conserved and immunodominant antigen. This peptide pool is an ideal tool for: Characterizing patient-specific or vaccine-induced T cell responses Ex vivo stimulation of EBV-specific T cells Epitope screening and immune profiling Immune monitoring in clinical trials of EBV-targeted vaccines or adoptive T cell therapies
Antigen Peptide EBV LMP-1 125-133 (HLA-A*02:01) YLLEMLWRL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
SSCSSCPLSK is a linear peptidic epitope (epitope ID60930) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays
SSCSSCPLTK is a linear mutated peptidic epitope (epitope ID60930) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assay
Antigen Peptide EBV LMP-2 419-427 (HLA-A*24:02) TYGPVFMCL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
EBV LMP-2 426-434 (HLA-A*02:01) CLGGLLTMV for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
Antigen Peptide EBV LMP1 159-167 (HLA-A*02:01) YLQQNWWTL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
Single peptide (PYLFWLAAI) for stimulation of human EBV LMP2(131-139)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*2402 allele.
Antigen Peptide EBV LMP2 HLA-A*0201 (FLYALALLL) for stimulation of human EBV LMP2(356-364)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. LYALALLL is a linear peptidic epitope studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus).
The peptide EBV LMP2 419-427 mutant 426S (HLA-A*24:02) with the amino acid sequence TYGPVFMSL is a linear peptidic epitope (epitope ID 67350) studied as part of Latent membrane protein 2 (UniProt:P13285) from Human herpesvirus 4 (Epstein Barr virus).EBV LMP2 419-427 mutant 426S (HLA-A*24:02) has been studied for immune reactivity in publications and has been tested in T cell assays and MHC ligand assays.
